The risk of adverse events following implantation of a glaucoma drainage device (GDD) is higher than the risk following either primary trabeculectomy (PT) or trabeculectomy with scarring (TS), according to results of a study published in the July 2008 issue of Ophthalmology.
The Glaucoma Foundation in the US has created an award scheme for innovation and excellence in glaucoma, recognizing the contribution of individuals who have "played a unique and significant role in promoting the medicine and science of glaucoma".
Performing LASIK in patients with glaucoma should be carefully considered before making the commitment because of changes in the eye that might result in lower IOP measurements, according to two ophthalmologists. PRK, however, might be a better option for this subgroup of patients, suggests one surgeon.
Timolol, latanoprost, and the fixed combinations of latanoprost/timolol (Xalcom; Pfizer) and dorzolamide/timolol (Cosopt; Merck) have equal efficacy and tolerability as well as equal levels of patient satisfaction, according to a study published online, ahead of print, by Graefe's Archive for Clinical and Experimental Ophthalmology.
INO-8875, an Adenosine 1 agonist in Phase I testing for the treatment of glaucoma, has begun patient enrolment.
A survey, released by the global campaign, All Eyes on Glaucoma, has revealed that more than 8.4 million people in Asia will be blinded by glaucoma by 2010 if they do not undergo treatment.
Should glaucoma drainage devices still be viewed as the last resort? asks Professor Walter Konen.
High caffeine intake is associated with an increased risk of high-tension primary open angle glaucoma (POAG) in subjects with a positive family history of glaucoma, according to a study published in the May 2008 issue of Investigative Ophthalmology & Visual Science.
Oxidative stress may play a role in the pathogenesis of primary open angle glaucoma (POAG), according to a study published in the June/July 2008 issue of the Journal of Glaucoma.
A new study shows that costs associated with glaucoma will more than double by 2025.
OT134, a laser therapy for the reduction of intraocular pressure, has completed the follow-up period of its first human clinical study.
The EyeRoute Image Management System, which provides a remote view of a Spectral Domain OCT system, has been introduced by Topcon Medical Systems.
Following positive clinical trial results, Allergan, the makers of bimatoprost, are submitting a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking a new indication for the prostaglandin analogue as an eyelash growth stimulant.
Eric Greve, one of the founding members of the European Glaucoma Society (EGS), has been honoured during a lunchtime ceremony at its quadrennial International Congress, held June 1–6 in Berlin, Germany.
A bimatoprost and timolol fixed combination (Ganfort; Allergan) is more effective at lowering intraocular pressure (IOP) over 12 weeks than latanoprost (Xalacom; Pfizer), according to results presented at the meeting of the European Glaucoma Society (EGS), held June 1–6 in Berlin.
The European Glaucoma Society (EGS) has officially unveiled the updated edition of its "Terminology and Guidelines for Glaucoma" at its 8th International Congress, held June 1?6 in Berlin.
Azarga (brinzolamide 1%/timolol 0.5% eye drops suspension; Alcon) and Cosopt (dorzolamide 2%/timolol 0.5% eye drops solution; Merck) are equally efficacious in IOP-lowering capacity, however, Azarga offers greater ocular comfort, according to a study presented at this week?s European Glaucoma Society congress in Berlin, Germany.
Increased fruit and vegetable consumption reduces the risk of glaucoma, according to a study reported in the June 2008 issue of the American Journal of Ophthalmology.
The diuretic agents, vasopressin-receptor antagonists, or vaptans, may have a use in the treatment of glaucoma, according to a study appearing in the 10 May, 2008 issue of The Lancet.
Attempts to control IOP through medical therapy tend to be first-line treatment although patient compliance and ocular surface integrity remain a concern
A proprietary miniature glaucoma device (Ex-PRESS; Optonol Ltd.) implanted under a partial-thickness scleral flap achieves significant decreases in intraocular pressure (IOP) in patients with glaucoma, according to Peter A. Netland, MD, PhD, reporting at the 2007 meeting of the Association for Research in Vision and Ophthalmology.
Organizers of the first-ever World Glaucoma Day are calling the international effort a success, with "amazing achievements" that helped raise awareness about the dangers of glaucoma and the need for screenings and treatment.
The World Glaucoma Day inspired glaucoma specialists around the world to rally local support in order to undertake an enormous task: to reduce the number of people who are unnecessarily going blind from a treatable condition.
The current gold standard for measuring intraocular pressure (IOP), the Goldmann tonometer (GAT), has considerable flaws. Dr Goldmann designed his tonometer to provide accurate measurements in eyes with average corneas, but we now know that many corneas vary significantly from the "average".
The medical treatment of glaucoma is limited by patient adherence to medications. By the end of a year, approximately half of patients are not refilling their medications as directed, and physicians are not able to tell those who are from those who are not.
